KR101874462B1

KR101874462B1 - Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component

Info

Publication number: KR101874462B1
Application number: KR1020170177765A
Authority: KR
Inventors: 김동선; 이윤미; 손은정
Original assignee: 한국 한의학 연구원
Priority date: 2017-12-22
Filing date: 2017-12-22
Publication date: 2018-07-05
Also published as: WO2019124863A1

Abstract

The present invention relates to a composition for preventing, ameliorating or treating atopic dermatitis comprising an extract of Omija leaf as an active ingredient. The extract of Omija, an active ingredient of the present invention, has antihistamine and NO production inhibitory effects on macrophages and mast cells It is. In particular, since the omija leaf extract has superior antihistaminic activity compared to the omija fruit or stem extract, the composition of the present invention can be usefully used as a composition for preventing, improving or treating an atopic dermatitis.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing, ameliorating or treating atopic dermatitis comprising an extract of Schizandra chinensis leaf extract as an active ingredient (Composition for prevention, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component)

The present invention relates to a composition for preventing, ameliorating or treating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.

Atopic dermatitis is a type of hypersensitivity that has recently become increasingly prevalent as its prevalence increases rapidly. From the immunological point of view, the major symptoms caused by immunological reactions of immunoglobulin E and allergens It is defined as a group of allergic diseases with a strong genetic tendency. In particular, atopic dermatitis, a typical symptom of atopy, accounts for 0.5 to 1% of the total population and 5 to 10% of the children have serious symptoms, but it is presumed that they are related to genetic factors and immune system deficiency The exact cause has not been elucidated, and it is expected that it will be alleviated somewhat through the improvement of environment and diet, but there is no fundamental treatment method.

However, although atopic dermatitis shows individual differences, most of them involve extreme itching, skin dryness, rashes, dirt, scabs, scaly skin (arthropods), and the resulting emotional anxiety, stress, Along with feelings of anger, other allergic diseases such as urticaria, metal allergies, asthma and allergic rhinitis, it is becoming a serious social problem that threatens the public health today. Meanwhile, representative drugs known to be effective for atopic dermatitis so far include steroids, antihistamines, antibiotics, non-steroids, and other sedatives and nerve stabilizers.

On the other hand, Schizandra chinensis ) is a dicotyledonous plant that is a magnolia plant of the Magnoliaceae. It grows mainly in valleys, the stem is brown and has the property of climbing trees. Leaves are alternate phyllotaxis, wide oval, long oval or ovate, with hairs on the back vein and tooth-like sawtooth on the edge. The flower is bloomed in June to July, is unisolated, and has a slightly reddish yellowish white color. After the flowering, the flower bud of the female flower grows to 3 ~ 5cm in length and the fruit runs in 穗狀. Fruits are berries and they are almost round and have several spines. It grows in red color from August to September and contains 1 to 2 reddish brown seeds. Younger children eat them as herbs. The fruit is mixed with the five flavors of sour, sweet, bitter, salty, and spicy. It has the effect of nourishing, gangjang, Jinhae, gadam, and perspiration in one room and it is prescribed in seawater, oilseed, gogal, dohan (sweat), acute hepatitis etc. . In the private sector, they make and drink omija tea and drink.

As a prior art related to Omija, Korean Patent Laid-Open Publication No. 2015-0027676 discloses a composition for preventing or treating metabolic syndrome-related diseases including an extract of Omija, and Korean Patent Publication No. 2017-0017388 discloses a composition for preventing or treating metabolic syndrome A composition for preventing or treating atopic dermatitis which comprises the extract of the present invention as an active ingredient has not been disclosed.

The present invention provides a composition for preventing, ameliorating or treating atopic dermatitis comprising an extract of Omija leaf as an active ingredient. The present invention provides a composition for preventing, improving or treating atopic dermatitis, And that the antihistamine effect and the NO scavenging activity are excellent. Thus, the present invention has been completed.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.

The present invention also provides a health functional food composition for preventing or ameliorating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.

Further, the present invention provides a cosmetic composition for improving atopic dermatitis comprising an extract of Omija leaf as an active ingredient.

In addition, the present invention provides a quasi-drug composition for improving atopic dermatitis comprising an extract of Omija leaf as an active ingredient.

FIG. 1 shows the results of analysis of the survival rate of mummified cells of Omima leaf extract of the present invention and MC9 mouse treated with Omiza fruit extract and Omija stem extract of Comparative Example.
FIG. 2 shows the results of confirming the antihistamine effect in the mast cell treated with the extract of Omija leaf of the present invention and the comparative example of Omija fruit extract and Omija stem extract. ***, **** indicates that the histamine content was significantly decreased compared with the negative control (Con) treated with Omija leaf extract, *** was p <0.001, **** was p < 0.0001.
FIG. 3 shows the results of confirming the NO (%) scavenging activity in the mummified leaf extract of the present invention and the mast cell treated with the Schizosacraliana fruit extract of Comparative Example. NMMA was a positive control and treated with 50 μM N-monomethyl arginine.
*, ***, and **** were statistically significantly decreased compared to the negative control group (p <0.05, p <0.001, ****, p < 0.0001.

The present invention relates to a pharmaceutical composition for preventing or treating atopic dermatitis, which comprises an extract of Omija leaf as an active ingredient.

The Omiza leaf extract may be produced by a method including, but not limited to, the following steps:

1) Extracting the dried powder of Omija leaf by adding an extraction solvent;

2) filtering the extract of step 1); And

3) Concentrating the filtrate obtained in step 2) under reduced pressure and drying to prepare an extract.

In step 1), the extraction solvent is preferably water, a C ₁ -C ₄ lower alcohol, or a mixture thereof, more preferably an ethanol extract, but is not limited thereto.

In the above production method, all the conventional methods known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction can be used for the extraction of the omiga leaves. The vacuum concentration in step 3) may be performed using a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.

The composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-mentioned active ingredient, and may be various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include capsules, powders, granules, tablets, pills, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid formulations for oral administration include suspensions, emulsions, syrups, aerosols and the like. Various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin which are commonly used simple diluents. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like. Intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine, intraperitoneal, or intracerebral injection methods are preferably selected for parenteral administration, and most preferably used for external skin application.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the level of effective amount depends on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

The dosage of the composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease, The dose is 0.01 to 2,000 mg / kg, preferably 30 to 500 mg / kg, more preferably 50 to 300 mg / kg, and can be administered 1 to 6 times a day. The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

The present invention also relates to a health functional food composition for preventing or ameliorating atopic dermatitis comprising an extract of Omija leaf as an active ingredient.

The health functional food composition may be prepared by any one of powder, granule, ring, tablet, capsule, candy, syrup and beverage, but is not limited thereto. When the health functional food composition of the present invention is used as a food additive, the above-mentioned Omiza leaf extract may be directly added, used in combination with other food or food ingredients, and suitably used according to a conventional method. The amount of active ingredient can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in the case of long-term ingestion intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range. There is no particular limitation on the kind of the food. Examples of the foods to which the above extract can be added include meat products, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health functional foods in a conventional sense.

When the composition of the present invention is used as a health drink, various flavors or natural carbohydrates may be added as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates are sugar alcohols such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as texturin and cyclotensitrin, and xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 g of the composition of the present invention. In addition to the above, the composition of the present invention may further comprise various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid concentrating agents, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. In addition, the composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.

The present invention also relates to a cosmetic composition for improving atopic dermatitis comprising an extract of Omija leaf as an active ingredient.

The composition may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion, foundation, wax foundation and spray But is not limited thereto.

When the formulation of the cosmetic composition of the present invention is a solution or an emulsion, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal fiber, a plant fiber, a wax, a paraffin, a starch, a tragacanth, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, Etc. may be used.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, Propellants such as carbon, propane-butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a cleansing agent containing an interfacial active agent, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyltaurate, sarcosinate , Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative or ethoxylated glycerol fatty acid ester.

The cosmetic composition of the present invention may contain at least one ingredient capable of improving atopic dermatitis, which exhibits the same or similar functions in addition to the active ingredient.

The cosmetic composition of the present invention can be directly applied to skin using biodegradable micro needles or patches.

The present invention also relates to a quasi-drug composition for improving atopic dermatitis comprising an extract of Omija leaf as an active ingredient.

In the present invention, the "quasi-drug composition" is a fiber, a rubber product or the like used for treating, alleviating, treating or preventing a disease of a human or an animal, Or products similar to those which are not machinery, preparations used for sterilization, insecticides and similar uses for the prevention of infections, for the purpose of diagnosis, treatment, alleviation, treatment or prevention of diseases of human beings or animals Means an article other than an apparatus, a machine or an apparatus, and an article other than an apparatus, a machine or an apparatus used for the purpose of giving a pharmacological effect to the structure and function of a person or an animal, But not limited to, personal hygiene products. The quasi-drug composition of the present invention may be contained at various weight%, preferably 0.00001 to 10% by weight, as long as it can improve the effect of atopic dermatitis.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.

Example 1. Preparation of Omiza leaf extract

15 l of 70% (v / v) ethanol was added to 1 kg of omza leaf dried powder, and the mixture was refluxed for 3 hours at 85 ° C. The filtrate was concentrated under reduced pressure at 50 ° C and dried to obtain an extract of Omija leaf .

Example 2. Cells Survival rate analysis

MC / 9 cells were diluted for each concentration for 24 hours, and cell viability was measured at 550 nm using a microplate reader (Molecular Devices, Sunnyvale, Calif., USA) by MTT assay.

As a result, as shown in Fig. 1, the extracts of Omiza fruit, leaf and stem showed almost no cytotoxicity.

Example 3. Analysis of antihistamine effect

The cells were treated with PMA (50 nM) and A23189 (1 μM) in MC / 9 cells at appropriate concentrations in a 48-well plate and the Omiza leaf extract of the present invention and the Omiza fruit extract and Omija stem extract 50, 100 占 퐂 / ml) and cultured for 24 hours. After culturing the supernatant, the amount of histamine was measured according to the manufacturer's method using a histamine ELISA assay kit.

As a result, as shown in FIG. 2, all of the extracts of Omija showed a concentration-dependent decrease in histamine concentration. Especially, in the case of Omija leaf extract, the content of histamine was remarkably higher than that of Omija extract or Omija stem extract It was confirmed that it was reduced.

Example 4. NO measurement

(25, 50, and 100 μg / ml), and LPS (500 ng / ml) were added to the RAW 274.7 cells, which had been divided into 48 well plates at appropriate concentrations, and the Omiza leaf extract of the present invention and Omija And cultured for 24 hours. The culture supernatant was taken and the amount of NO was measured according to the manufacturer's method using Griess reagent.

As a result, as shown in Fig. 3, the Omiza leaf extract significantly reduced the amount of NO induced by LPS treatment.

Claims

A pharmaceutical composition for preventing or treating atopic dermatitis comprising an extract of ethanol or methanol of an omija leaf as an active ingredient.

delete

The pharmaceutical composition for preventing or treating atopic dermatitis according to claim 1, further comprising a carrier, an excipient or a diluent in addition to the ethanol or methanol extract of Omiza leaf.

A health functional food composition for preventing or ameliorating atopic dermatitis comprising ethanol or methanol extract of Omija leaf as an active ingredient.

The health functional food composition according to claim 4, wherein the composition is prepared from any one of powder, granule, ring, tablet, capsule, candy, syrup and beverage.

A cosmetic composition for improving atopic dermatitis comprising an extract of ethanol or methanol of an omija leaf as an active ingredient.

7. The composition of claim 6, wherein the composition is selected from a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion, foundation, wax foundation and spray A cosmetic composition for improving atopic dermatitis characterized by being produced in any one of the formulations.

A quasi-drug composition for improving atopic dermatitis comprising an extract of ethanol or methanol as an active ingredient.